Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0AP9E
|
|||
Drug Name |
Trilaciclib
|
|||
Synonyms |
G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra
Click to Show/Hide
|
|||
Indication | Small-cell lung cancer [ICD-11: 2C25.Y] | Approved | [1] | |
Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [2] | ||
Company |
G1 Therapeutics Research Triangle Park, NC
|
|||
Structure |
Download2D MOL |
|||
Formula |
C24H30N8O
|
|||
Canonical SMILES |
CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
|
|||
InChI |
1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
|
|||
InChIKey |
PDGKHKMBHVFCMG-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1374743-00-6
|
|||
PubChem Compound ID |
References | Top | |||
---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.